A
Alumis Inc. (ALMS)
NMS – Real vaqt narxi. Valyuta: USD
26.40
+1.37 (5.47%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
26.29
-0.11 (-0.42%)
Bozordan keyin: Jun 26, 2026, 5:54 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
26.40
+1.37 (5.47%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
26.29
-0.11 (-0.42%)
Bozordan keyin: Jun 26, 2026, 5:54 PM EDT
Alumis Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, autoimmün kasalliklar uchun dori vositalarini ishlab chiqish va tijoratlashtirishga qaratilgan. Kompaniya psoriaz va tizimli qizil yug'richni davolash uchun tirozin kinaz 2 (TYK2) ingibitori bo'lgan envudeucitinibni; va neyroimmflamatuar va neyrodegenerativ kasalliklarni davolash uchun 1-bosqichda bo'lgan markaziy asab tizimiga kiruvchi allosterik TYK2 ingibitori A-005 ni taklif etadi. Shuningdek, u qalqonsimon bez kasalliklarini davolash uchun IGF-1R ga yo'naltirilgan monoklonal antitelasini va immunitet disfunksiyasini bartaraf etish uchun interferon regulyator omili 5 (IRF5) ni ishlab chiqmoqda. Kompaniya ilgari Esker Therapeutics, Inc. nomi bilan tanilgan va 2022 yil yanvar oyida Alumis Inc. nomini o'zgartirgan. Alumis Inc. 2021 yilda ro'yxatga olingan va Janubiy San-Frantsisko, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. David M. Goldstein Ph.D. | Chief Scientific Officer |
| Dr. Jorn Drappa M.D., Ph.D. | Chief Medical Officer & Head of Research and Development |
| Mr. John R. Schroer C.F.A. | Chief Financial Officer |
| Mr. Kolbot By Ph.D. | Senior VP & Head of Technical Operations |
| Mr. Mark Bradley | Chief Development Officer |
| Mr. Martin Babler Ph.D. | President, CEO & Chairman |
| Mr. Philip Nunn Ph.D. | Senior VP of Pharmacology & Project Team Leader |
| Mr. Roy C. Hardiman J.D. | Chief Business & Strategy Officer |
| Ms. Claire Langrish Ph.D. | Senior VP & Head of Immunology and Translational Science |
| Ms. Sanam Pangali J.D. | Chief Legal Officer & Corporate Secretary |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-18 | DEFA14A | tm266546d3_defa14a.htm |
| 2026-05-18 | DEF 14A | tm266546-1_def14a.htm |
| 2026-05-18 | ARS | tm266548d2_ars.pdf |
| 2026-05-14 | 8-K | alms-20260514x8k.htm |
| 2026-05-14 | 10-Q | alms-20260331x10q.htm |
| 2026-03-30 | 8-K | tm269978d1_8k.htm |
| 2026-03-19 | S-3ASR | tm269184-1_s3asr.htm |
| 2026-03-19 | 8-K | alms-20260319x8k.htm |
| 2026-03-19 | 10-K | alms-20251231x10k.htm |
| 2026-01-30 | S-8 | tm263983d1_s8.htm |